About OctreoPharm Sciences
OctreoPharm Sciences is a Healthcare company based in Berlin (Germany) founded in 2009, and was acquired by Ipsen in May 2015. Theranostic compounds are developed for diagnosing and treating neuroendocrine tumors. OctreoPharm Sciences has raised $7.23 million across 1 funding round from investors including Ipsen, KfW and ELSA. OctreoPharm Sciences offers products and services including Theranostics Development. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Neurological Cancer. Its legal entity is OctreoPharm Sciences GmbH.
Company details
OctreoPharm Sciences focuses on the development of radioactive labeled pharmaceuticals for the diagnosis and treatment of neuroendocrine tumours. It is developing theranostic compounds which are based on the antagonistic peptide JR11 which is binding with high affinity to somatostatin receptor subtype 2, predominantly expressed on neuroendocrine tumours (NETs). OPS202 is its diagnostic compound to detect NETs whole OPS201 is aimed for tumor cell-selective internal peptide receptor radionuclide therapy (PRRT) on NETs.
- Headquarters Berlin, Germany
- Stage Acquired
- SectorsHealthcare
- Website octreopharmsciences.com
- Social LinkedIn
- Acquired by Ipsen (May 2015)
- Legal Name Octreopharm Sciences Gmbh
Products & Services of OctreoPharm Sciences
OctreoPharm Sciences offers a comprehensive portfolio of products and services, including Theranostics Development.
Advances oncology treatments through radiochemistry expertise.
Funding Insights of OctreoPharm Sciences
OctreoPharm Sciences has successfully raised a total of $7.23M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.23 million completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.23M
- Total Rounds 1
- Last Round Series A — $7.23M
- First Round $7.23M
(Apr 2011)
- Investors Count 3
All 1 funding rounds of OctreoPharm Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2011 | $7.23M | Series A | – | Eckert Life Science Accelerator, KfW | – |
4 investors in total: 4 institutional.
Investors in OctreoPharm Sciences
OctreoPharm Sciences has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Ipsen, KfW and ELSA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A Berlin-based life science incubator and venture capital provider. | 1992 | elsalifescience.com | Berlin, Germany | |
Venture capital firm focused on multiple sectors | ibbventures.de | Berlin, Germany | ||
Consumer and SME loans are provided across Germany. | 1948 | kfw.de | Frankfurt Am Main, Germany | |
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | 1929 | ipsen.com |
Investor details for OctreoPharm Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of OctreoPharm Sciences
3 dated milestones of OctreoPharm Sciences across 6 years, from founding to its latest funding, stage changes and deals.
- Founded OctreoPharm Sciences is founded.
- Funding First funding round of $7.2M.
- Exit Acquired by Ipsen.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OctreoPharm Sciences
OctreoPharm Sciences was founded in 2009 and raised its 1st funding round 2 years after it was founded.
OctreoPharm Sciences is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.
OctreoPharm Sciences is a funded company, having raised a total of $7.23M across 1 funding round to date. The company's 1st funding round was a Series A of $7.23M, raised on Apr 2011.
OctreoPharm Sciences focuses on the development of radioactive labeled pharmaceuticals for the diagnosis and treatment of neuroendocrine tumours. It is developing theranostic compounds which are based on the antagonistic peptide JR11 which is binding with high affinity to somatostatin receptor subtype 2, predominantly expressed on neuroendocrine tumours (NETs). OPS202 is its diagnostic compound to detect NETs whole OPS201 is aimed for tumor cell-selective internal peptide receptor radionuclide therapy (PRRT) on NETs.
OctreoPharm Sciences offers Theranostics Development.
OctreoPharm Sciences has 4 investors. Key investors include Ipsen, KfW, ELSA, and IBB Ventures.
OctreoPharm Sciences operates through Octreopharm Sciences Gmbh.
Yes. OctreoPharm Sciences was acquired by Ipsen in May 2015.